gm2-klh vaccine
Melanoma (Skin)
European Organisation for Research and Treatment of Cancer - EORTCvaccinePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
152 Active assets in the Melanoma (Skin) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Alpha-Interferon MIPO Clinic | Phase 3 | BBB |
DACARBAZINE Linnaeus Therapeutics, Inc. | Phase 3 | BBB |
TIL City of Hope Medical Center | Phase 2 | BBB |
CIS-DIAMMINEDICHLOROPLATINUM II MIPO Clinic | Phase 3 | BBB |
Tyrosinase Peptide University of Southern California | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
gm2-klh vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →